Prognose

Analytikernes gennemsnitlige kursmål er 22,41 € (+65,27 %). Medianen er 22,41 € (+65,27 %).

Køb	9
Behold	5
Sælg	1

Nyheder Til nyhedsfeedet

NovoCure: market launches of Optune Pax gain momentum and drive international growth

NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » Mere på de.investing.com
NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices

NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Mere på finance.yahoo.com
Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed

The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Mere på de.investing.com

Virksomhedstal

I det seneste kvartal havde NovoCure en omsætning på 160,86 mio. € og et nettoresultat på -13,72 mio. €

(EUR)	juni 2026	YoY
Omsætning	160,86 mio.	19,39 %
Bruttofortjeneste	124,84 mio.	25,41 %
Nettoresultat	-13,72 mio.	59,71 %
EBITDA	-9,25 mio.	65,41 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	1,69 mia. €
Antal aktier	116,45 mio.
Højeste/laveste i 52 uger	18,49 € - 8,46 €
Udbytte	Nej
Beta	1,01
P/E (PE Ratio)	-12,96
PEG (PEG Ratio)	-4,09
K/I (PB Ratio)	5,78
P/S (PS Ratio)	2,81

Virksomhedsprofil

NovoCure Limited, ein Onkologieunternehmen, beschäftigt sich mit der Entwicklung, Herstellung und Vermarktung von Geräten zur Behandlung von Tumorfeldern (TTFields) für die Behandlung von soliden Tumoren in den Vereinigten Staaten, Europa, dem Nahen Osten, Afrika, Japan und Großchina. Zu seinen TTFields-Geräten gehören Optune für die Behandlung von Glioblastomen und Optune Lua für die Behandlung von malignen Pleuramesotheliomen. Das Unternehmen hat außerdem laufende oder abgeschlossene klinische Studien zur Untersuchung von TTFields bei Hirnmetastasen, Magenkrebs, Glioblastom, Leberkrebs, nicht-kleinzelligem Lungenkrebs, Bauchspeicheldrüsenkrebs und Eierstockkrebs. NovoCure Limited wurde im Jahr 2000 gegründet und hat seinen Hauptsitz in Saint Helier, Jersey.